•  
  •  
  •  
  •  

2025-08-31 22:23:06

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism

Keywords Selected:  SolaraActivePharmaSciences

Research

  • Solara Active Pharma Sciences - Recovering business provides respite - ICICI Securities

Stock Report

  • Solara Active Pharma Sciences Ltd consolidated Q1FY26 PAT rises to Rs. 10.52 crores
  • Solara Active Pharma Sciences Ltd Q4 FY25 consolidated loss at Rs. 2.10 crores
  • Solara Active Pharma Sciences Ltd consolidated Q3 FY2025 PAT at Rs. 8.09 crores
  • Solara Active Pharma Sciences Ltd consolidated Q2 FY2025 net profit at Rs. 8.01 crores
  • Solara Active Pharma Sciences Ltd reports consolidated loss of Rs. 13.46 crores in Q1 FY25
  • Solara announces closure of Rights Issue
  • Solara Active Pharma Sciences Ltd finalizes Rights Issue terms
  • Solara Active Pharma Sciences Ltd consolidated Q2 FY2024 loss at Rs. 17.16 crores
  • Solara Active Pharma Sciences Ltd Q1FY24 consolidated loss widens to Rs. 19.55 crore
  • USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations
  • Solara Active Pharma Ltd board approves rights issue of Rs. 450 crores
  • Solara Active Pharma Sciences Ltd consolidated Q4 FY2023 net profit up at Rs. 3.77 crores
  • Solara's Cuddalore facility successfully completes EU GMP Inspection
  • USFDA concludes inspection at Solara's Visakhapatnam facility with Zero 483 inspectional observations
  • Solara Active Pharma Sciences Ltd's Cuddalore facility completes WHO PQ inpsection
  • Solara Active Pharma Sciences Ltd Q3FY23 consolidated profit at Rs. 0.45 crore
  • Solara Active Pharma Sciences Ltd Q2 FY2022-23 consolidated loss at Rs. 9.96 crores
  • Solara receives European Approval to manufacture Ibuprofen from its flagship Vizag Facility
  • Solara Active Pharma Sciences Ltd posts consolidated loss of Rs. 16.43 crores in Q1FY23
  • Solara Active Pharma Sciences Ltd Q4 FY2022 consolidated PAT at Rs. 1.88 crore
  • Solara announces the return of Hariharan Subramaniam as its new CFO
  • Mr. Rajender Juwadi Rao to take charge as MD and CEO of Solara Active Pharma Sciences Ltd from Mar 1, 2022
  • Solara Active Pharma Sciences Q3FY22 consolidated loss at Rs. 139.87 crores
  • Solara Active Pharma Sciences Ltd Q2FY22 consolidated PAT slides to Rs. 29.71 crore

Latest Post

  • Titan unveils 8 new brand outlets across Delhi NCR, strengthening their retail footprint with 1000+ stores in FY26
  • Zigly Unveils New Experience Centre at Phoenix Marketcity, Strengthens Mumbai Presence
  • XTGlobal Infotech Ltd and ICICI Bank Ltd enter into loan agreement
  • NCC Limited receives orders worth Rs. 788.34 crore
  • Thomas Cook India & SOTC Travel ink long-term strategic MOU with Queensland Tourism


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024